Technical Analysis for CLLS - Cellectis S.A.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Inside Day | Range Contraction | -2.55% | |
| Gapped Up | Strength | -2.55% | |
| 20 DMA Support | Bullish | -1.55% | |
| Pocket Pivot | Bullish Swing Setup | -1.55% | |
| Volume Surge | Other | -1.55% | |
| Gapped Up | Strength | -1.55% |
| Alert | Time |
|---|---|
| Down 3% | about 21 hours ago |
| Down 2 % | about 21 hours ago |
| Down 1% | about 21 hours ago |
| Possible Inside Day | 1 day ago |
| 10 DMA Support | 2 days ago |
Get a Trading Assistant
- Earnings date: 11/04/2024
Cellectis S.A. Description
Cellectis, a biopharmaceutical company, develops cancer products based on engineered T cells armed with a chimeric antigen receptor for the treatment of liquid and solid tumors. Its lead product candidate, UCART19, is an allogeneic engineered T cell product for the treatment of CD19 expressing hematologic malignancies that developed in chronic lymphocytic leukemia and acute lymphoblastic leukemia indications. The company's products also include hematopoietic tumors, such as UCART123 and UCART33 for acute myeloid leukemia indications, and UCART-BCMA and UCART38 for multiple myeloma indications, as well as solid tumors comprising UCART5T4 for various solid tumor indications and UCART-EgfrVIII for glioblastoma indications. In addition, it is focused on life sciences to build products based on genome engineering technologies in various fields and markets. Cellectis was founded in 1999 and is based in Paris, France.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Solid Tumors Acute Myeloid Leukemia Leukemia Blastoma Glioblastoma Multiple Myeloma Hematologic Malignancies Oncogenes Genome Chimeric Antigen Receptor Chronic Lymphocytic Leukemia Lymphocytic Leukemia Adoptive Cell Transfer Tumors Of The Hematopoietic And Lymphoid Tissues CD19 Cell Product Acute Lymphoblastic Leukemia Cellectis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.7735 |
| 52 Week Low | 1.7 |
| Average Volume | 56,259 |
| 200-Day Moving Average | 2.35 |
| 50-Day Moving Average | 1.99 |
| 20-Day Moving Average | 1.86 |
| 10-Day Moving Average | 1.90 |
| Average True Range | 0.11 |
| RSI (14) | 50.25 |
| ADX | 17.96 |
| +DI | 19.04 |
| -DI | 17.14 |
| Chandelier Exit (Long, 3 ATRs) | 1.67 |
| Chandelier Exit (Short, 3 ATRs) | 2.03 |
| Upper Bollinger Bands | 2.01 |
| Lower Bollinger Band | 1.71 |
| Percent B (%b) | 0.66 |
| BandWidth | 16.33 |
| MACD Line | -0.01 |
| MACD Signal Line | -0.03 |
| MACD Histogram | 0.0219 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.97 | ||||
| Resistance 3 (R3) | 1.97 | 1.95 | 1.96 | ||
| Resistance 2 (R2) | 1.95 | 1.93 | 1.95 | 1.96 | |
| Resistance 1 (R1) | 1.93 | 1.93 | 1.92 | 1.93 | 1.95 |
| Pivot Point | 1.91 | 1.91 | 1.91 | 1.91 | 1.91 |
| Support 1 (S1) | 1.89 | 1.89 | 1.88 | 1.89 | 1.87 |
| Support 2 (S2) | 1.87 | 1.89 | 1.87 | 1.86 | |
| Support 3 (S3) | 1.85 | 1.87 | 1.86 | ||
| Support 4 (S4) | 1.85 |
